Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chene Gardner, president and CEO of Cancer Therapeutics, anticipates to finalize the new agreement within the next 90 days
Subscribe to our email newsletter
Cancer Therapeutics has signed a letter of intent to acquire another 26% interest in NanoTherapies, bringing the former’s stake to 51% and giving it a controlling interest of NanoTherapies.
Reportedly, as per the terms of the agreement, six million restricted shares are subject to formal approval by the managing member and governing board of directors of NanoTherapies. In addition, a full audit of NanoTherapies needs to be completed for a binding agreement.
Recently, Cancer Therapeutics has completed acquisition of 25 % stake in NanoTherapies, making it the company’s first acquisition. Chene Gardner, president and CEO of Cancer Therapeutics, has said that he would expect to finalize the new agreement within the next 90 days.